Literature DB >> 6609729

Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation.

K C Anderson, M P Bates, B L Slaughenhoupt, G S Pinkus, S F Schlossman, L M Nadler.   

Abstract

A series of monoclonal antibodies that define B cell restricted and associated antigens was utilized in an attempt to characterize tumors of B lineage and to relate these tumors to B cell differentiative stages. Antigens that were previously shown to be B cell restricted on normal B lymphocytes were similarly expressed only on B cell malignancies. In contrast, antigens that were B cell associated were also found on tumors of other lineages. Moreover, on the basis of cell surface phenotypes, tumors of B cell origin were divided into three major subgroups, which corresponded to the level of differentiation of the malignant tumor cell: pre-B cell stage (non-T acute lymphoblastic leukemia and chronic myelocytic leukemia in lymphoid blast crisis); the mid-B cell stage (chronic lymphocytic leukemia, poorly differentiated lymphomas); and secretory B cell stage (large cell lymphomas and plasma cell tumors). A hypothetical model is derived that relates the malignant B cell to its normal cellular counterpart on the basis of cell surface expression of this panel of B cell-restricted and B cell-associated antigens.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6609729

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  128 in total

Review 1.  Promising approaches in acute leukemia.

Authors:  J Cortes; H M Kantarjian
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

2.  Structure of the genes encoding the CD19 antigen of human and mouse B lymphocytes.

Authors:  L J Zhou; D C Ord; S A Omori; T F Tedder
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

3.  Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.

Authors:  Mayuka Horikawa; Veronique Minard-Colin; Takashi Matsushita; Thomas F Tedder
Journal:  J Clin Invest       Date:  2011-10-24       Impact factor: 14.808

4.  Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy.

Authors:  Alberto Lerario; Filippo Cogiamanian; Chiara Marchesi; Marzia Belicchi; Nereo Bresolin; Laura Porretti; Yvan Torrente
Journal:  BMC Musculoskelet Disord       Date:  2010-07-11       Impact factor: 2.362

Review 5.  Immunomodulation in the treatment of haematological malignancies.

Authors:  Michela Cesco-Gaspere; Emma Morris; Hans J Stauss
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

6.  Establishment of the DU.528 human lymphohemopoietic stem cell line.

Authors:  J Kurtzberg; S H Bigner; M S Hershfield
Journal:  J Exp Med       Date:  1985-11-01       Impact factor: 14.307

Review 7.  Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.

Authors:  Cédric Rossi; Marie-Lorraine Chrétien; René-Olivier Casasnovas
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

8.  TSPAN33 is a novel marker of activated and malignant B cells.

Authors:  Van Phi Luu; Peter Hevezi; Felipe Vences-Catalan; José Luis Maravillas-Montero; Clayton Alexander White; Paolo Casali; Luis Llorente; Juan Jakez-Ocampo; Guadalupe Lima; Natalia Vilches-Cisneros; Juan Pablo Flores-Gutiérrez; Leopoldo Santos-Argumedo; Albert Zlotnik
Journal:  Clin Immunol       Date:  2013-08-15       Impact factor: 3.969

9.  Selective activation of antigen-experienced T cells by anti-CD3 constrained on nanoparticles.

Authors:  Ying-Chun Lo; Michael A Edidin; Jonathan D Powell
Journal:  J Immunol       Date:  2013-10-04       Impact factor: 5.422

10.  Immunophenotyping of B lymphocytes by multiparametric flow cytometry in bone marrow aspirates of healthy adults.

Authors:  H G Höffkes; G Schmidtke; U Schmücker; M Uppenkamp; G Brittinger
Journal:  Ann Hematol       Date:  1995-09       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.